Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Insulet
(NASDAQ:PODD)
Intraday
$169.18
0
[0.00%]
After-Hours
$169.18
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$169.18
0
[0.00%]
At close: Mar 27
$169.18
0
[0.00%]
PreMarket: 4:20PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Insulet Stock (NASDAQ:PODD)
Insulet Stock (NASDAQ: PODD)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, March 20, 2024
Insulet Announced That Ana Maria Chadwick Has Been Appointed Executive Vice President, Chief Financial Officer And Treasurer, Effective April 22, 2024
Benzinga Newsdesk
-
Mar 20, 2024, 6:01AM
Friday, March 08, 2024
Insulet Says Randomized Controlled Trial (OP5-003) Demonstrates Omnipod 5 Automated Insulin Delivery System Is Superior To Pump Therapy
Benzinga Newsdesk
-
Mar 8, 2024, 6:02AM
Tuesday, March 05, 2024
Insulet To Present Results From First Omnipod 5 Randomized Controlled Trial (OP5-003) At International Conference on Advanced Technologies & Treatments for Diabetes
Benzinga Newsdesk
-
Mar 5, 2024, 6:04AM
Thursday, February 29, 2024
Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit)
Piero Cingari
-
Feb 29, 2024, 4:57PM
Monday, February 26, 2024
On Thursday February 22, Insulet Gave Q1 2024 Revenue Growth Guidance Of 17%-20%; For FY24, The Company Expects Revenue Growth In The Range Of 12%-17%
Benzinga Newsdesk
-
Feb 26, 2024, 3:20PM
Surgery Partners Posts Weak Sales, Joins Kosmos Energy, Moderna And Other Big Stocks Moving Lower On Monday
Avi Kapoor
-
Feb 26, 2024, 11:18AM
Insulet shares are trading lower after Barclays maintained an Equal-Weight rating on the stock and lowered its price target from $214 to $213.
Benzinga Newsdesk
-
Feb 26, 2024, 10:13AM
Barclays Maintains Equal-Weight on Insulet, Lowers Price Target to $213
Benzinga Newsdesk
-
Feb 26, 2024, 7:06AM
Friday, February 23, 2024
JP Morgan Maintains Overweight on Insulet, Raises Price Target to $225
Benzinga Newsdesk
-
Feb 23, 2024, 3:48PM
Analyst Scoreboard: 5 Ratings For Insulet
Benzinga Insights
-
Feb 23, 2024, 2:00PM
Insulet shares are trading lower after the company reported Q4 financial results.
Benzinga Newsdesk
-
Feb 23, 2024, 8:33AM
Nasdaq, S&P 500 Set for Mixed Open After Nvidia Euphoria: Analyst Picks Major Market Catalyst This Year If There Are No Rate Cuts
Shanthi Rexaline
-
Feb 23, 2024, 7:34AM
Thursday, February 22, 2024
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights
-
Feb 22, 2024, 4:31PM
Insulet shares are trading lower after the company reported Q4 financial results.
Benzinga Newsdesk
-
Feb 22, 2024, 4:26PM
Insulet: Q4 Earnings Insights
Benzinga Insights
-
Feb 22, 2024, 4:15PM
Insulet Q4 2023 Adj EPS $1.40 Beats $0.66 Estimate, Sales $509.80M Beat $461.05M Estimate
Benzinga Newsdesk
-
Feb 22, 2024, 4:09PM
Nasdaq, S&P 500 Futures Jump As Nvidia Surge Raises 'FOMO' Rally Hopes: Analyst Tells Why Jobs Data Holds Key For Momentum
Shanthi Rexaline
-
Feb 22, 2024, 7:22AM
Earnings Scheduled For February 22, 2024
Benzinga Insights
-
Feb 22, 2024, 5:27AM
Thursday, February 08, 2024
Insulet Unusual Options Activity
Benzinga Insights
-
Feb 8, 2024, 3:45PM
Wednesday, February 07, 2024
Insulet Has Received CE Mark Approval Under The European Medical Device Regulation For The Added Compatibility Of The Abbott FreeStyle Libre 2 Plus Sensor With Insulet's Omnipod 5 Automated Insulin Delivery System For Individuals Aged Two Years And Older
Benzinga Newsdesk
-
Feb 7, 2024, 6:42AM
Monday, February 05, 2024
Stifel Maintains Hold on Insulet, Raises Price Target to $208
Benzinga Newsdesk
-
Feb 5, 2024, 4:11PM
Monday, January 22, 2024
Insulet Unusual Options Activity For January 22
Benzinga Insights
-
Jan 22, 2024, 2:30PM
Thursday, December 21, 2023
Insulet shares are trading higher after Baird upgraded the stock from Neutral to Outperform and raised its price target from $180 to $238.
Benzinga Newsdesk
-
Dec 21, 2023, 11:05AM
Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday
Avi Kapoor
-
Dec 21, 2023, 7:36AM
Expert Ratings For Insulet
Benzinga Insights
-
Dec 21, 2023, 7:00AM
Baird Upgrades Insulet to Outperform, Raises Price Target to $238
Benzinga Newsdesk
-
Dec 21, 2023, 5:15AM
Friday, December 15, 2023
Big Players' Recent Trades in PODD Options
Benzinga Insights
-
Dec 15, 2023, 2:31PM
Monday, December 04, 2023
What 8 Analyst Ratings Have To Say About Insulet
Benzinga Insights
-
Dec 4, 2023, 8:00AM
Morgan Stanley Upgrades Insulet to Overweight, Raises Price Target to $234
Benzinga Newsdesk
-
Dec 4, 2023, 7:27AM
Wednesday, November 15, 2023
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
-
Nov 15, 2023, 12:35PM
Monday, November 13, 2023
Stocks Pause Ahead Of CPI Report; Commodities, Tesla, Boeing Surge On Rising China Hopes: What's Driving Markets Monday?
Shanthi Rexaline
-
Nov 13, 2023, 1:35PM
Shares of medical device and diabetes care stocks are trading higher in reaction to the presentation of SELECT data by Novo Nordisk. Raymond James said it did not believe there were any major surprises and the data could be seen as 'modestly de-risking.'
Benzinga Newsdesk
-
Nov 13, 2023, 11:38AM
Friday, November 10, 2023
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
-
Nov 10, 2023, 12:35PM
Tuesday, November 07, 2023
What Stocks Drove The Recent Record Rally? A Breakdown You Can't Miss
Piero Cingari
-
Nov 7, 2023, 1:13PM
Saturday, November 04, 2023
Barron's Weekend Stock Picks: Chevron, Apple, Disney And Insulet's Stock Increase
Justin Chan
-
Nov 4, 2023, 4:37PM
Friday, November 03, 2023
Piper Sandler Maintains Overweight on Insulet, Lowers Price Target to $250
Benzinga Newsdesk
-
Nov 3, 2023, 4:32PM
Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday
Lisa Levin
-
Nov 3, 2023, 11:30AM
Omnipod Insulin Pump Working Well For Insulet, Lifts Annual Forecast
Vandana Singh
-
Nov 3, 2023, 9:57AM
Insulet shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 guidance.
Benzinga Newsdesk
-
Nov 3, 2023, 9:21AM
Thursday, November 02, 2023
Insulet shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 guidance.
Benzinga Newsdesk
-
Nov 2, 2023, 5:06PM
Insulet Sees Q4 Revenue Growth Of 22% To 25%; FY23 Revenue Raising Its Expected Revenue Growth To A Range Of 26% To 27%
Benzinga Newsdesk
-
Nov 2, 2023, 4:03PM
Insulet Q3 EPS $0.71 Beats $0.40 Estimate, Sales $432.70M Beat $414.22M Estimate
Benzinga Newsdesk
-
Nov 2, 2023, 4:02PM
Earnings Scheduled For November 2, 2023
Benzinga Insights
-
Nov 2, 2023, 4:56AM
Monday, October 23, 2023
Insulet Secures FDA 510(k) Clearance For The Omnipod 5 App For iPhone
Benzinga Newsdesk
-
Oct 23, 2023, 6:04AM
Wednesday, October 18, 2023
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
-
Oct 18, 2023, 1:35PM
Tuesday, October 17, 2023
JP Morgan Maintains Overweight on Insulet, Lowers Price Target to $162
Benzinga Newsdesk
-
Oct 17, 2023, 12:06PM
Monday, October 16, 2023
Expert Ratings for Insulet
Benzinga Insights
-
Oct 16, 2023, 4:00PM
Leerink Partners Initiates Coverage On Insulet with Outperform Rating, Announces Price Target of $184
Benzinga Newsdesk
-
Oct 16, 2023, 12:02PM
Wednesday, October 11, 2023
Shares of diabetes and glucose monitoring stocks are trading lower. The sector may be down on the FDA's announcement of a Digital Health Advisory Committee as well as early signs of efficacy in Novo Nordisk's Ozempic kidney trial. The sector has been under pressure this year amid the popularity of weight loss drugs.
Benzinga Newsdesk
-
Oct 11, 2023, 3:38PM
Tuesday, October 10, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Oct 10, 2023, 1:09PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch